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Health facilities included in this trial, location and date of launch of the intervention
Clusters were antenatal care (ANC) clinics in health facilities. The 10 participating ANC clinics were selected purposely by the Ministry of Health (MOH) according to its programmatic activities and priorities and with geographical representation of the three regions of Mozambique (North, Center and South). Table S1 shows the health facilities listed chronologically according to the start of the intervention. It also shows the date of the launch of the intervention in each facility as well as its location. Table S1 : Health facilities listed in chronological order according to the start of the intervention. The date of the launch of the intervention in each facility is also shown as well as well as its location. In addition, the table shows the approximate number of nurses providing ANC care in each facility and the number of first ANC visits attended in 2011.
Components of the ANC visits as per national guidelines
National guidelines from the Ministry in Health of Mozambique promote an ANC model including a series of evidencebased interventions for each ANC visit. Table S2 provides the interventions to be delivered to the women by ANC visit. 
Photos of the kits
Fig S1 and S2 present photos of Kit A; a ready-made box that is easily carried. 
Detailed list of outcomes and definitions
For the purpose of the data analysis, the definitions of the outcomes had to be operationalized to be able to compute them from the data collected in the ANC logbook. For example, according to national guidelines for ANC, mebendazole should be given to women in the second or third trimester of pregnancy only. Under these guidelines, women were eligible to receive mebendazole if they had more than or equal to 12 weeks gestation and thus those at less than 12 weeks gestation were excluded from the denominator. Tables S5 and S6 list the outcomes and how they were defined and any other considerations for first and follow-up ANC visits, respectively. Section 12 of this Supplementary Appendix presents the logbook from where the data was extracted. 
Screening practices
Blood pressure measured in follow-up visits • Proportion of eligible who were given antiretrovirals • Antiretrovirals were not provided in the ANC kits but were part of the intervention
All women who had a positive HIV test in followup visits Folic acid and ferrous sulfate received in follow-up visits
• All pregnant women should receive 1 iron pill per day. In practice they are given 30 pills at each appointment and are told to come back after 30 days. The fact that they received the pills is recorded in their hand-held record (caderneta); only when they receive the 3rd dose of 30 pills, it is registered in the ANC book. Thus, the logbook does not provide the information required for the analysis since it registers only the women that have received the 3rd dose (which is never in the 1st ANC visit) • Folic acid/ferrous sulphate provided in ANC kit
Not computed
Mebendazole received in follow-up visits
• According to national guidelines, mebendazole is only given in the first ANC visit
Sulphadoxine-pyrimethamine received in follow-up visits
• Proportion of eligible women who were given fansidar • According to the protocol of the MoH, fansidar should not be given early in pregnancy. At the beginning of the trial the norm was to start at 20 weeks. At some point during the trial this changed to 12 weeks. Conservatively, we used the 20 weeks as the cutoff throughout.
• Fansidar should not be given to women who are HIV+ (if they are taking Cotrimoxazole and/or ART)
All women at 20 weeks' or more gestation age, who are not taking cotrimoxazol and/or ART, attending follow-up visits
Bed nets received in follow-up visits
• The bed nets were ANC Kit D so were part of the intervention but their supply was secured through other partners, and distribution by MoH • The trial only strengthened this intervention by reminding nurses in the refresher training • Major stock outs are rare but there were often short delays in distribution to health facilities. In these cases, nurses would give the woman her net on her follow-up visit.
Tetanus toxoid received in follow-up visits
• The vaccine was not provided in the ANC kits • Stock outs are very rare in this item • What the trial did was to remind nurses in refresher training that they should vaccinate women; and in one center a cool box was provided so that they could vaccinate in all ANC rooms without having to refer the woman to another room.
• Women that show they have been vaccinated previously (ie.
By showing vaccination card or patient hand-held record (caderneta) should not be re-vaccinated. We would not expect 100% of women to receive the vaccine.
• Thus, the readings from the logbook are not adequate for the analysis of this outcome Not computed 6. Practice delivery rates at baseline (Step 1) 
Data management and data quality assurance
This was a pragmatic trial which used routine data as its primary data source. ANC nurses in Mozambique are required to register all antenatal visits in standardized logbooks which are designed and provided by the MOH. While the MOH compiles data from monthly summaries generated by the nurses on the basis of the data in the logbooks, there is no system in place to systematically digitalize this information. Women have a hand-held record (caderneta) where the healthcare provider writes the information related to pregnancy. Women do not have clinical records, and the logbook was the only source document for the trial. Data management procedures were developed and implemented in all 10 participating ANC clinics with the purpose of transferring the data in the logbook to the data management center. A simple coding system was introduced for the logbooks in order to avoid the ambiguities present in the standard system for completing the logbooks, and nurses were trained in how to complete the logbooks correctly using the coding system. Research assistants hired for the trial regularly reviewed the logbooks in each ANC clinic, took digital photos of each page of the logbook and sent them to the data management center in Maputo. We originally intended to link first and follow-up ANC visits for each woman by assigning a unique study subject ID at enrolment; however, implementation of such a system was in practice challenging and it is only available for a subset of the data.
Several data quality audit and monitoring activities were implemented. Special consideration was taken to avoid bias due to changes in data quality associated with the implementation of the intervention. With this aim and to the extent possible, procedures and monitoring for data collection were deployed independently from the deployment and monitoring of the intervention.
In order to minimize potential issues with quality of the routine data collected from the logbooks, three independent data monitoring procedures were implemented. First, we conducted routine monitoring visits to verify that the trial data collection instrument -the registration logbook-was being completed appropriately and that the data management processes were being done according to standardized procedures. These visits were conducted every two to three months in both control and intervention sites. Second, once in each ANC clinic, data monitors directly observed 100 consecutive first ANC visits per facility, and registered the results of tests and procedures in a monitoring log. The data in this monitoring log was then compared to the same records in the logbooks completed by the nurses. Third, a set of surveys was conducted by interviewing a sample of 100 consecutive women at each ANC clinic as they were leaving their first ANC visit. To compare data quality between the intervention and control periods, these data surveys were conducted at three different times -at the start, middle and end of the data collection period.
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Diagram of first and follow-up ANC visits independently

Clinics
Steps Table S9 : Trial diagram for follow-up visits. Each step equals 2 months except for step 1 which was 3 months. The ANC clinics are listed in Table S1 of this Supplementary Appendix.
Effect of the intervention in follow-up antenatal care visits
We originally intended to link first and follow-up ANC visits for each woman by assigning a unique study subject ID at enrolment; however, implementation of such a system was in practice challenging and it is only available for a subset of the data. In the analysis of follow-up ANC visits, women may contribute with more than one visit (i.e. repeated visits), and as such these observations are not independent. Since we were only able to identify repeated visits in a subset of women by using the unique subject ID, the main analysis was conducted without adjusting for repeating visits. However, a sensitivity analysis was conducted in this subset of women, including subject ID in the regression models as a random variable to assess the impact of the lack of independence of multiple observation on inference estimates. The impact of these adjustments on the precision of the estimates was very small. These analyses were computed by fitting generalized linear mixed models with the lme4 statistical package in R (version 3.1). Table S11 shows the effect of the intervention in secondary outcomes in follow-up visits. A statistically and clinically significant increase in practice coverage was observed in four of the six secondary outcomes evaluated in follow-up visits. Table S11 shows that 4015 of 85058 women (4·7%) were screened for anemia in the control period, as compared to 48319 of 64621 women (74·8%) in the intervention period (adjusted odds ratio, 140·97; 99% CI, 123·60 to 160·79; P<0·001). For proteinuria, 2804 of 85058 women (3·3%) were screened for proteinuria in the control period, as compared to 59517 of 64621 women (92·1%) in the intervention period (adjusted odds ratio, 160·20; 99% CI, 136·37 to 188·19; P<0·001). For blood pressure, 57697 of 85058 women (67·8%) had their blood pressure measured in the control period, as compared to 64001 of 64621 women (99·0%) in the intervention period (adjusted odds ratio, 475·61; 99% CI, 398·70 to 567·35; P<0·001). Preventive treatment for malaria (IPT) was provided to 35254 of 68045 women (51·8%) in the control period, as compared with 33610 of 52141 women (64·5%) in the intervention period (adjusted odds ratio, 1·37; 99% CI, 1·30 to 1·45; P<0·001).
For HIV practices in follow-up visits, the intervention did not have an effect. Table S11 shows that 522 of 75017 women (0·7%) was screened for HIV in the control period, as compared to 349 of 58009 women (0·6%) in the intervention period (adjusted odds ratio, 1·24; 99% CI, 0·90 to 1·70; P=0·005). Lastly, 30 of 54 HIV-positive women (55·6%) was treated with ARV in the control period, as compared to 15 of 25 women (60%) in the intervention period (adjusted odds ratio, 1·36; 99% CI, 0·25 to 7·34; P=0·068).
The overall pattern of improvement is less dramatic in follow-up visit than in first visits. This is thought to be due to less clear national guidelines and protocols referring to follow-up visits. HIV repeat screening is only tested in some cases and HIV treatment continues at each visit. Under the stepped-wedge design, the adjusted odds ratios are calculated with the use of all data points in the intervention period versus the control period and so represent the average odds of exposure to the intervention. § Intracluster correlation coefficient during the control period Figure S3 . Outcome rates, by step and ANC clinic; follow-up ANC visits. Each cell contains the proportion of women who received each specific practice in the corresponding ANC clinic and step.
*When the denominator to compute the cell rate is 0, cells are coloured in white.
Steps (2 month periods)
Steps (2 month periods) 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 6 7 8 9 10 11 A Screening for Anaemia (N=148 679) B Screening for proteinuria (N=149 679) 1 0 98 98 100 95 100 100 100 99 99 99 0 97 89 99 95 100 100 100 99 96 100 2 0 0 98 99 100 100 100 100 98 100 100 0 1 97 99 100 100 98 99 100 97 100 3 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
Effect of the intervention in composite outcome
We computed this score for first ANC visits and included practices targeting all or most women as opposed to practices that are intended for a small subgroup such as treatment for syphilis or HIV. To compute this score, one point was added for each intended screening or treatment intervention delivered during the ANC visits. The practices included in the score were screening for high blood pressure, proteinuria, anaemia, syphilis and HIV, and treatment for parasitic worms. These add up to a maximum score value of six points.
The intervention was also found to have a statistically significant effect on the composite outcome score (adjusted mean difference 1·72; 99% CI 1·70-1·74; p<0·0001). Figure S4 . Composite outcome score, by step and ANC clinic; first ANC visits. A waiver of consent forms for participating women was obtained since this study is considered of minimal risk (risks of daily life, and includes the risks associated with routine physical examinations and review of medical records) and it is developed in the context of regular prenatal care and using as research records those used in health care process (no data collection tools have been developed to gather data regarding women´s health for the study). Recommendations provided for The Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials were taken into account in the design of this trial. 2.4 2.7 3.5 3.4 3.6 3.7 4.9 5.5 5.6 5.5 5.6 7 1.8 3.1 3.5 3.1 3.5 3.7 3.3 5.5 5.7 5.6 5.6 8 2.4 2.5 2.6 3.2 3.0 2.7 2.6 3.0 5.3 5.6 5.7 9 2.2 4.1 4.8 4.6 4.0 3.6 3.7 3.5 3.8 5.7 5.7 10 1.8 2.1 2.1 2.7 2.3 2.6 2.7 2.4 2.1 2.2 4.9 Results at the individual or cluster level as applicable and a coefficient of intracluster correlation (ICC or k) for each primary outcome Table 4 17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended Table 4 Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory 
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